Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 470

1.

Dual modulation of neuron-specific microRNAs and the REST complex promotes functional maturation of human adult induced neurons.

Birtele M, Sharma Y, Kidnapillai S, Lau S, Stoker T, Barker RA, Rylander Ottosson D, Drouin-Ouellet J, Parmar M.

FEBS Lett. 2019 Sep 19. doi: 10.1002/1873-3468.13612. [Epub ahead of print]

PMID:
31535361
2.

Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs JR; International Parkinson's Disease Genomics Consortium, Chitrala KN, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen O, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27845. [Epub ahead of print]

PMID:
31505070
3.

Huntington's disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory.

Harris KL, Armstrong M, Swain R, Erzinclioglu S, Das T, Burgess N, Barker RA, Mason SL.

Cortex. 2019 Aug 13;119:417-427. doi: 10.1016/j.cortex.2019.07.014. [Epub ahead of print]

4.

A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice.

Heath CJ, O'Callaghan C, Mason SL, Phillips BU, Saksida LM, Robbins TW, Barker RA, Bussey TJ, Sahakian BJ.

Front Neurol. 2019 Aug 9;10:858. doi: 10.3389/fneur.2019.00858. eCollection 2019.

5.

Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD.

Stuart S, Lawson RA, Yarnall AJ, Nell J, Alcock L, Duncan GW, Khoo TK, Barker RA, Rochester L, Burn DJ; ICICLE-PD study group.

Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27813. [Epub ahead of print]

PMID:
31442355
6.

Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Neurol Genet. 2019 Jul 9;5(4):e348. doi: 10.1212/NXG.0000000000000348. eCollection 2019 Aug. Erratum in: Neurol Genet. 2019 Aug 15;5(4):e354.

7.

A Professional Standard for Informed Consent for Stem Cell Therapies.

Sugarman J, Barker RA, Charo RA.

JAMA. 2019 Aug 12. doi: 10.1001/jama.2019.11290. [Epub ahead of print] No abstract available.

PMID:
31403653
8.

Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.

Tan MMX, Malek N, Lawton MA, Hubbard L, Pittman AM, Joseph T, Hehir J, Swallow DMA, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Bresner C, Foltynie T, Hardy J, Wood N, Ben-Shlomo Y, Grosset DG, Williams NM, Morris HR.

Brain. 2019 Sep 1;142(9):2828-2844. doi: 10.1093/brain/awz191.

9.

Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease.

Barker RA; TRANSEURO consortium.

Nat Med. 2019 Jul;25(7):1045-1053. doi: 10.1038/s41591-019-0507-2. Epub 2019 Jul 1. Review.

PMID:
31263283
10.

Loss of FBXO7 results in a Parkinson's-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway.

Stott SR, Randle SJ, Al Rawi S, Rowicka PA, Harris R, Mason B, Xia J, Dalley JW, Barker RA, Laman H.

J Pathol. 2019 May 29. doi: 10.1002/path.5312. [Epub ahead of print]

PMID:
31144295
11.

L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.

Malek N, Kanavou S, Lawton MA, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams NM, Wood N, Morris HR, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2019 May 14. pii: S1353-8020(19)30243-3. doi: 10.1016/j.parkreldis.2019.05.022. [Epub ahead of print]

PMID:
31105012
12.

Targeting Huntingtin Expression in Patients with Huntington's Disease.

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Phase 1–2a IONIS-HTTRx Study Site Teams.

N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6.

PMID:
31059641
13.

Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Martín-Bastida A, Lao-Kaim NP, Roussakis AA, Searle GE, Xing Y, Gunn RN, Schwarz ST, Barker RA, Auer DP, Piccini P.

Brain. 2019 Jul 1;142(7):2023-2036. doi: 10.1093/brain/awz120.

PMID:
31056699
14.

Parkinson disease and growth factors - is GDNF good enough?

Kirkeby A, Barker RA.

Nat Rev Neurol. 2019 Jun;15(6):312-314. doi: 10.1038/s41582-019-0180-6. No abstract available.

PMID:
30948845
15.

WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis.

Kaiser K, Gyllborg D, Procházka J, Salašová A, Kompaníková P, Molina FL, Laguna-Goya R, Radaszkiewicz T, Harnoš J, Procházková M, Potěšil D, Barker RA, Casado ÁG, Zdráhal Z, Sedláček R, Arenas E, Villaescusa JC, Bryja V.

Nat Commun. 2019 Apr 2;10(1):1498. doi: 10.1038/s41467-019-09298-4.

16.

Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease.

Horton MC, Nopoulos P, Nance M, Landwehrmyer GB, Barker RA, Squitieri F; REGISTRY Investigators of the European Huntington’s Disease Network, Burgunder JM, Quarrell O.

J Huntingtons Dis. 2019;8(2):181-193. doi: 10.3233/JHD-180306.

17.

Hyperosmotic stress induces cell-dependent aggregation of α-synuclein.

Fragniere AMC, Stott SRW, Fazal SV, Andreasen M, Scott K, Barker RA.

Sci Rep. 2019 Feb 19;9(1):2288. doi: 10.1038/s41598-018-38296-7.

18.

Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease.

Stoker TB, Torsney KM, Barker RA.

In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 3.

19.

The Differential Diagnosis of Parkinson’s Disease.

Greenland JC, Barker RA.

In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 6.

20.

Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach.

Jensen MP, Barker RA.

J Huntingtons Dis. 2019;8(1):9-22. doi: 10.3233/JHD-180320.

PMID:
30636742
21.

Ensuring safety in public playgrounds is everybody's business.

Barker RA, Eager D, Sharwood LN.

Med J Aust. 2019 Jan;210(1):9-11.e1. doi: 10.5694/mja18.00549. Epub 2018 Dec 28. No abstract available.

PMID:
30636314
22.

Platelet abnormalities in Huntington's disease.

Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Rowley JW, Cloutier N, Tremblay MÈ, Vincent AT, Gould PV, Chouinard S, Weyrich AS, Rondina MT, Barker RA, Boilard E, Cicchetti F.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):272-283. doi: 10.1136/jnnp-2018-318854. Epub 2018 Dec 19.

23.

The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease.

White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, McMahon HT, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Nov 20;9:946. doi: 10.3389/fneur.2018.00946. eCollection 2018.

24.

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. doi: 10.1136/jnnp-2018-318337. Epub 2018 Jul 25.

25.

Exploring causality of the association between smoking and Parkinson's disease.

Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.

Int J Epidemiol. 2019 Jun 1;48(3):912-925. doi: 10.1093/ije/dyy230.

26.

iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia.

Li L, Roh JH, Chang EH, Lee Y, Lee S, Kim M, Koh W, Chang JW, Kim HJ, Nakanishi M, Barker RA, Na DL, Song J.

Exp Neurobiol. 2018 Oct;27(5):350-364. doi: 10.5607/en.2018.27.5.350. Epub 2018 Oct 31.

27.

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.

Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C.

Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.

28.

Portrait of blood-derived extracellular vesicles in patients with Parkinson's disease.

Lamontagne-Proulx J, St-Amour I, Labib R, Pilon J, Denis HL, Cloutier N, Roux-Dalvai F, Vincent AT, Mason SL, Williams-Gray C, Duchez AC, Droit A, Lacroix S, Dupré N, Langlois M, Chouinard S, Panisset M, Barker RA, Boilard E, Cicchetti F.

Neurobiol Dis. 2019 Apr;124:163-175. doi: 10.1016/j.nbd.2018.11.002. Epub 2018 Nov 5.

PMID:
30408591
29.

Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis.

Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Oct 16;9:870. doi: 10.3389/fneur.2018.00870. eCollection 2018.

30.

Ensuring safety in public playgrounds is everybody's business.

Barker RA, Eager D, Sharwood LN.

Med J Aust. 2018 Oct 29. [Epub ahead of print] No abstract available.

PMID:
30359559
31.

Emerging Treatment Approaches for Parkinson's Disease.

Stoker TB, Torsney KM, Barker RA.

Front Neurosci. 2018 Oct 8;12:693. doi: 10.3389/fnins.2018.00693. eCollection 2018. Review.

32.

Outcome of cell suspension allografts in a patient with Huntington's disease.

Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, Tremblay MÈ, Gould P, Rosser AE, Dunnett SB, Piccini P, Barker RA, Cicchetti F.

Ann Neurol. 2018 Dec;84(6):950-956. doi: 10.1002/ana.25354. Epub 2018 Oct 25.

33.

Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease.

Gravell R, Duncan GW, Khoo TK, Burn DJ, Sayer AA, Barker RA, Lawson RA, Yarnall AJ.

J Parkinsons Dis. 2018;8(4):511-515. doi: 10.3233/JPD-181428.

PMID:
30248064
34.

Platelet-derived extracellular vesicles in Huntington's disease.

Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Weiss A, Chouinard S, Barker RA, Boilard E, Cicchetti F.

J Neurol. 2018 Nov;265(11):2704-2712. doi: 10.1007/s00415-018-9022-5. Epub 2018 Sep 12.

PMID:
30209650
35.

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease.

Palfi S, Gurruchaga JM, Lepetit H, Howard K, Ralph GS, Mason S, Gouello G, Domenech P, Buttery PC, Hantraye P, Tuckwell NJ, Barker RA, Mitrophanous KA.

Hum Gene Ther Clin Dev. 2018 Sep;29(3):148-155. doi: 10.1089/humc.2018.081.

36.

Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation.

Pircs K, Petri R, Madsen S, Brattås PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Brückner M, Lundh SH, Petersén Å, Déglon N, Hébert SS, Parmar M, Barker RA, Jakobsson J.

Cell Rep. 2018 Aug 7;24(6):1397-1406. doi: 10.1016/j.celrep.2018.07.017.

37.

The clinical heterogeneity of Parkinson's disease and its therapeutic implications.

Greenland JC, Williams-Gray CH, Barker RA.

Eur J Neurosci. 2019 Feb;49(3):328-338. doi: 10.1111/ejn.14094. Epub 2018 Oct 14.

PMID:
30059179
38.

Categorising Visual Hallucinations in Early Parkinson's Disease.

Clegg BJ, Duncan GW, Khoo TK, Barker RA, Burn DJ, Yarnall AJ, Lawson RA.

J Parkinsons Dis. 2018;8(3):447-453. doi: 10.3233/JPD-181338.

PMID:
30040741
39.

Regenerative Therapies for Parkinson's Disease: An Update.

Stoker TB, Barker RA.

BioDrugs. 2018 Aug;32(4):357-366. doi: 10.1007/s40259-018-0294-1. Review.

PMID:
30027398
40.

The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series.

Collins LM, Williams-Gray CH, Morris E, Deegan P, Cox TM, Barker RA.

J Neurol. 2018 Aug;265(8):1789-1794. doi: 10.1007/s00415-018-8908-6. Epub 2018 May 29.

41.

Abnormalities of age-related T cell senescence in Parkinson's disease.

Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL.

J Neuroinflammation. 2018 May 28;15(1):166. doi: 10.1186/s12974-018-1206-5.

42.

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2018 May 24;8(1):8266. doi: 10.1038/s41598-018-23083-1.

43.

New approaches for brain repair-from rescue to reprogramming.

Barker RA, Götz M, Parmar M.

Nature. 2018 May;557(7705):329-334. doi: 10.1038/s41586-018-0087-1. Epub 2018 May 16. Review.

PMID:
29769670
44.

The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?

Barker RA, Carpenter MK, Forbes S, Goldman SA, Jamieson C, Murry CE, Takahashi J, Weir G.

Stem Cell Reports. 2018 May 8;10(5):1429-1431. doi: 10.1016/j.stemcr.2018.04.010. Review.

45.

Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study.

Minett T, Su L, Mak E, Williams G, Firbank M, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn D, O'Brien JT.

J Neurol. 2018 Jul;265(7):1528-1539. doi: 10.1007/s00415-018-8873-0. Epub 2018 Apr 25.

PMID:
29696499
46.

Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development.

Castiglioni V, Faedo A, Onorati M, Bocchi VD, Li Z, Iennaco R, Vuono R, Bulfamante GP, Muzio L, Martino G, Sestan N, Barker RA, Cattaneo E.

Cereb Cortex. 2019 May 1;29(5):2115-2124. doi: 10.1093/cercor/bhy092.

PMID:
29688344
47.

Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations.

Collins LM, Drouin-Ouellet J, Kuan WL, Cox T, Barker RA.

Version 2. F1000Res. 2017 Sep 26 [revised 2018 Jan 1];6:1751. doi: 10.12688/f1000research.12090.2. eCollection 2017.

48.

Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts.

Shrigley S, Pircs K, Barker RA, Parmar M, Drouin-Ouellet J.

J Vis Exp. 2018 Feb 5;(132). doi: 10.3791/56904.

49.

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker.

Mason SL, Daws RE, Soreq E, Johnson EB, Scahill RI, Tabrizi SJ, Barker RA, Hampshire A.

Ann Neurol. 2018 Mar;83(3):532-543. doi: 10.1002/ana.25171. Epub 2018 Mar 13.

50.

Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.

Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709. doi: 10.1136/jnnp-2017-317348. Epub 2018 Jan 29.

Supplemental Content

Loading ...
Support Center